Breast Cancer Liquid Biopsy Market2

PORTLAND, OR, UNITED STATES, July 11, 2023/EINPresswire.com/ -- Allied Market Research has recently published a research study titled "Global Outlook and Forecast 2023-2030 for the Breast Cancer Liquid Biopsy Market." This study assesses market risks through a comprehensive analysis, identifies opportunities, and provides strategic and tactical decision-making support for the period 2023-2030. The market study is segmented by key regions that are driving the marketization process. The report offers insights into market research and development, growth drivers, and the evolving investment structure of the Global Breast Cancer Liquid Biopsy Market. Several key players are profiled in the study, including Biocept, F. Hoffmann-La Roche (Foundation Medicine), Fluxion Biosciences, Menarini Group (Menarini Silicon Biosystems), Myriad Genetics, NeoGenomics Laboratories, Qiagen, Sysmex, Thermo Fisher Scientific.

Click To get FREE SAMPLE PDF (Including Full TOC, Table & Figures): https://www.alliedmarketresearch.com/request-sample/7983

Breast Cancer Liquid Biopsy Market Statistics: The global breast cancer liquid biopsy market was valued at $87,641 thousand in 2019, and is projected to reach $357,051 thousand by 2027, registering a CAGR of 19.2% from 2019 to 2027.

Breast Cancer Liquid Biopsy Market Growth Drivers:

Non-invasive Testing: Liquid biopsy offers a non-invasive alternative to traditional tissue biopsies for detecting and monitoring breast cancer. It involves the analysis of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) in the blood. This non-invasive nature of liquid biopsy attracts patients and healthcare providers, as it reduces the need for invasive procedures and enables more frequent testing.

Early Detection and Monitoring: Liquid biopsy allows for early detection of breast cancer and monitoring of the disease progression. By analyzing the genetic alterations and mutations present in CTCs or ctDNA, liquid biopsy can provide insights into the presence of cancer, its stage, and treatment response. Early detection and continuous monitoring can lead to timely intervention, personalized treatment plans, and improved patient outcomes.

Personalized Medicine: Liquid biopsy enables the identification of specific genetic mutations and alterations in breast cancer patients. This information helps in tailoring treatment strategies and selecting targeted therapies that are more likely to be effective for individual patients. The ability to detect genetic changes associated with drug resistance also allows for the adjustment of treatment plans to optimize outcomes.

Rising Prevalence of Breast Cancer: Breast cancer is one of the most common types of cancer globally, and its incidence is increasing. The growing prevalence of breast cancer is driving the demand for effective diagnostic tools such as liquid biopsy. Liquid biopsy offers a less invasive and more accessible method for detecting and monitoring breast cancer, which can help in early intervention and improved patient outcomes.

Technological Advancements: The breast cancer liquid biopsy field has witnessed significant technological advancements, including improvements in the sensitivity and specificity of liquid biopsy tests. Advancements in molecular biology techniques, next-generation sequencing (NGS), and digital PCR have enhanced the accuracy and reliability of liquid biopsy assays. These advancements have increased the adoption of liquid biopsy in clinical practice.

Have Any Query? Ask Our Expert @: https://www.alliedmarketresearch.com/purchase-enquiry/7983

The segments and sub-section of Breast Cancer Liquid Biopsy market is shown below:

By Product & Service: Reagent Kits, Instruments, and Services

By Circulating Biomarker: Circulating Tumor Cells, Extracellular Vesicles, and Circulating Tumor DNA

By Application: Diagnostics, Prognostics, and Risk Assessment

Some of the key players involved in the Market are: Biocept, F. Hoffmann-La Roche (Foundation Medicine), Fluxion Biosciences, Menarini Group (Menarini Silicon Biosystems), Myriad Genetics, NeoGenomics Laboratories, Qiagen, Sysmex, Thermo Fisher Scientific.

Important years considered in the Breast Cancer Liquid Biopsy study:
Historical year – 2017-2021; Base year – 2021; Forecast period** – 2022 to 2030 [** unless otherwise stated]

If opting for the Global version of Breast Cancer Liquid Biopsy Market; then below country analysis would be included:
– North America (USA, Canada and Mexico)
– Europe (Germany, France, the United Kingdom, Netherlands, Italy, Nordic Nations, Spain, Switzerland and Rest of Europe)
– Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India, Southeast Asia and Rest of APAC)
– South America (Brazil, Argentina, Chile, Colombia, Rest of countries etc.)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Turkey, Nigeria, South Africa, Rest of MEA)

Key Questions Answered with this Study:
1) What makes Breast Cancer Liquid Biopsy Market feasible for long term investment?
2) How influencing factors driving the demand of Breast Cancer Liquid Biopsy in next few years?
3) Territory that may see steep rise in CAGR & Y-O-Y growth?
4) What geographic region would have better demand for product/services?
5) What opportunity emerging territory would offer to established and new entrants in Breast Cancer Liquid Biopsy market?
6) What strategies of big players help them acquire share in mature market?
7) Know value chain areas where players can create value?
8) What is the impact analysis of various factors in the Global Breast Cancer Liquid Biopsy market growth?
9) Risk side analysis connected with service providers?

Introduction about Breast Cancer Liquid Biopsy Market
Breast Cancer Liquid Biopsy Market Size (Sales) Market Share by Type (Product Category)
Breast Cancer Liquid Biopsy Market by Application/End Users
Breast Cancer Liquid Biopsy Sales (Volume) and Market Share Comparison by Applications
Global Breast Cancer Liquid Biopsy Sales and Growth Rate (2020-2030)
Breast Cancer Liquid Biopsy Competition by Players/Suppliers, Region, Type, and Application
Breast Cancer Liquid Biopsy (Volume, Value, and Sales Price) table defined for each geographic region defined.
Breast Cancer Liquid Biopsy Players/Suppliers Profiles and Sales Data
Key Raw Materials Analysis & Price Trends
Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis
……..and view more in complete table of Contents

Connect to Analysts @ https://www.alliedmarketresearch.com/connect-to-analyst/7983

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Allied Market Research
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.